Compare IMCR & SCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMCR | SCL |
|---|---|---|
| Founded | 2008 | 1932 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2016 | 1994 |
| Metric | IMCR | SCL |
|---|---|---|
| Price | $28.63 | $53.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | $66.33 | ★ $75.00 |
| AVG Volume (30 Days) | ★ 304.3K | 122.4K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.23% |
| EPS Growth | ★ 30.39 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | $249,428,000.00 | ★ $1,803,737,000.00 |
| Revenue This Year | $14.57 | $6.60 |
| Revenue Next Year | $8.21 | $5.27 |
| P/E Ratio | $117.72 | ★ N/A |
| Revenue Growth | ★ 43.05 | N/A |
| 52 Week Low | $27.56 | $41.82 |
| 52 Week High | $40.71 | $68.00 |
| Indicator | IMCR | SCL |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 62.14 |
| Support Level | $27.69 | $48.52 |
| Resistance Level | $31.56 | $68.00 |
| Average True Range (ATR) | 1.14 | 1.35 |
| MACD | 0.08 | 0.28 |
| Stochastic Oscillator | 22.02 | 88.48 |
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Stepan Co manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on product type. The surfactants segment, which generates the majority of revenue, sells cleaning agents used in detergents, shampoos, body wash, fabric softeners, toothpastes, and other personal-care products. The polymers segment sells polyurethane used to manufacture rigid foam for thermal insulation, as well as phthalic anhydride used to make plastic components for the construction, automotive, and boating industries. The specialty products segment sells chemicals used in food and flavoring. The majority of Stepan's revenue comes from the United States, followed by France, Poland, the United Kingdom, Brazil, Mexico, and other countries.